New therapeutic strategies for the treatment of male lower urinary tract symptoms
Datum
2016Language
en
Schlagwort
Zusammenfassung
Male lower urinary tract symptoms (LUTS) are prevalent in the general population, especially in those of advanced age, and are characterized by notable diversity in etiology and presentation, and have been proven to cause various degrees of impairment on quality of life. The prostate has traditionally been regarded as the core cause of male LUTS. As a result, medical treatment aims to provide symptomatic relief and effective management of progression of male LUTS due to benign prostatic enlargement. In this context, α1-blockers, phosphodiesterase-5 inhibitors, and 5α-reductase inhibitors have long been used as monotherapies or in combination treatment to control voiding LUTS. There is accumulating evidence, however, that highlights the role of the bladder in the pathogenesis of male LUTS. Current research interests have shifted to bladder disorders, and medical management is aimed at the bladder. Muscarinic receptor antagonists and the newly approved β3-adrenergic agonist mirabegron aim to alleviate the most bothersome storage LUTS and thus improve quality of life. As voiding and storage LUTS frequently coexist, combination therapeutic strategies with α1-blockers and antimuscarinics or β3-agonists have been introduced to manage symptoms effectively. Anti-inflammatory agents, vitamin D3-receptor analogs, and cannabinoids represent treatment modalities currently under investigation for use in LUTS patients. Furthermore, luteinizing hormone-releasing hormone antagonists, transient receptor-potential channel blockers, purinergic neurotransmission antagonists, Rho-kinase inhibitors, and inhibitors of endothelin-converting enzymes could have therapeutic potential in LUTS management, but still remain in the experimental setting. This article reviews new strategies for the medical treatment of male LUTS, which are dictated by the potential role of the bladder and the risk of benign prostatic hyperplasia progression. Moreover, combination treatments and therapies currently under investigation are also presented. © 2016 Dimitropoulos and Gravas.
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies
Michel M.C., Gravas S. (2016)Introduction: We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss ... -
Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials
Tasoudis P.T., Arvaniti C.K., Adamou A.T., Belios I., Stone J.H., Horick N., Sagris D., Dalekos G.N., Ntaios G. (2022)Objective: To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. Data Sources: A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was ... -
Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial
Krishnan K., Scutt P., Woodhouse L., Adami A., Becker J.L., Cala L.A., Casado A.M., Chen C., Dineen R.A., Gommans J., Koumellis P., Christensen H., Collins R., Czlonkowska A., Lees K.R., Ntaios G., Ozturk S., Phillips S.J., Sprigg N., Szatmari S., Wardlaw J.M., Bath P.M., ENOS Investigators (2016)Background and purpose More than 50% of patients with acute intracerebral hemorrhage (ICH) are taking antihypertensive drugs before ictus. Although antihypertensive therapy should be given long term for secondary prevention, ...